Read More

Verrica Pharmaceuticals Announces Acceptance Of Abstract Featuring Clinical Data Of VP-315 For The Treatment Of Basal Cell Carcinoma At The American Academy Of Dermatology Association’s 2023 Innovation Academy Meeting

Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced

VRCA